1. Home
  2. LAKE vs BMEA Comparison

LAKE vs BMEA Comparison

Compare LAKE & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lakeland Industries Inc.

LAKE

Lakeland Industries Inc.

HOLD

Current Price

$8.51

Market Cap

98.2M

Sector

Health Care

ML Signal

HOLD

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.38

Market Cap

90.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LAKE
BMEA
Founded
1982
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
98.2M
90.5M
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
LAKE
BMEA
Price
$8.51
$1.38
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
7
Target Price
$17.33
$8.71
AVG Volume (30 Days)
88.0K
914.7K
Earning Date
03-18-2026
01-01-0001
Dividend Yield
1.36%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$167,211,000.00
N/A
Revenue This Year
$19.87
N/A
Revenue Next Year
$8.32
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2554.14
N/A
52 Week Low
$7.77
$0.87
52 Week High
$21.19
$3.08

Technical Indicators

Market Signals
Indicator
LAKE
BMEA
Relative Strength Index (RSI) 30.27 55.21
Support Level $7.77 $1.24
Resistance Level $9.67 $1.43
Average True Range (ATR) 0.35 0.09
MACD -0.09 0.01
Stochastic Oscillator 4.24 67.44

Price Performance

Historical Comparison
LAKE
BMEA

About LAKE Lakeland Industries Inc.

Lakeland Industries Inc manufactures and sells safety garments and accessories for the industrial protective clothing market. Its product segments include Disposables, Chemicals, Fire, Gloves, High Visibility, High-Performance Wear, and Wovens. Its customers include integrated oil, chemical/petrochemical, utilities, automobile, steel, glass, construction, smelting, munition plants, janitorial, pharmaceutical, and mortuaries, as well as scientific and medical laboratories. Its geographical segments include the United States, Latin America, Canada, Asia, Mexico, Europe (United Kingdom), and Other Foreign.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Share on Social Networks: